EASL- Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C

Transgene to Present New Data on TG1050 and TG4040 to Treat Chronic Hepatitis B and C at EASL 2013 

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:

“TG4040 has recently completed successful phase 2 trial in patients with CHC”

Transgene SA (Paris:TNG) (Euronext Paris: FR0005175080), a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and infectious diseases, today announced that favourable pre-clinical and clinical data on two Transgene products – TG1050 and TG4040 to treat chronic hepatitis B (CHB) and chronic hepatitis C (CHC), respectively – will be presented in oral presentations at this year’s European Association for the Study of the Liver (EASL) Conference (Amsterdam, Netherlands, April 24-28, 2013). The full abstracts are available at http://www.easl.eu.

“We are delighted to have the opportunity to present data at EASL, Europe’s largest liver conference. TG1050 is a novel immunotherapeutic to treat CHB that has shown very promising preclinical results and will soon be moving to early clinical development” stated Philippe Archinard, Chairman and CEO of Transgene. He added: “In addition to the preclinical proof-of-concept data published in September 20121, we have today released supplementary information, obtained in pre-clinical naïve and HBV murine models, on the immunogenicity of TG1050 and its capacity to induce long-term T cell response. This evidence further underlines our belief in the product’s potential to become an important new first in class immunotherapeutic to treat CHB, an area of unmet medical need.”

“TG4040 has recently completed successful phase 2 trial in patients with CHC” stated Nathalie Adda, Chief Medical Officer of Transgene. She added: “Following interim data published in April last year for TG4040 in combination with PegIFNα2a and ribavirin, we report the final results of the phase 2 HCVac trial with sustained viral response at 24 weeks (SVR24) and additional immunogenicity, specific T-cell and humoral responses. The study has demonstrated that pre-treatment with TG4040 has a positive impact on viral response as shown by cEVR and SVR improvement compared to PegIFN alpha 2a and Ribavirin alone. HCV Immunotherapy now could be explored in combination with an IFN-free DAA regimen.”

1 Poster Presentation of TG1050 at the International HBV Meeting in Oxford, England

The oral presentations will take place on Friday, April 26 and Saturday, April 27, 2013.

Friday, April 26, Session entitled: HCV Direct Acting Antivirals (abstract No 62)

Phase 2 HCVac Study of TG4040 immunotherapeutic in combination with PegIFNα2a and ribavirin in genotype 1 CHC treatment naïve patients: SVR24 Final Results

Oral presentation by Pr. Heiner Wedemeyer, Principal Investigator of the HCVac study, University of Hanover, Germany

Session Time: 16:00-18:00

Saturday, April 27, Session entitled: Hepatitis B and D Experimental (abstract No 130)

A Multivalent Adenovirus-Based Immunotherapeutic for Treatment of Chronic Hepatitis B Induces Broad, Robust and Polyfunctional T Cells in Naïve and HBV Tolerant Mice

Oral presentation by Dr. Perrine Martin, Scientific Coordinator of the Hepatitis B Program, Department of Infectious Diseases, Transgene SA.

Session Time: 15:30-17:30

About TG1050

The novel immunotherapeutic product TG1050 developed by Transgene to treat chronic infection by hepatitis B is based on a recombinant non-replicative human adenovirus serotype 5, expressing multiple specific HBV antigens (Core, Polymerase and Envelope) from genotype D. The product has been designed to prime de novo and/or stimulate functional T cells expected to control the HBV replication and to elicit viral clearance.

According to the World Health Organization’s (WHO) estimates, 350 million people are chronic carriers (WHO, 2009) of HBV. Hepatitis B is more common in some parts of the world than others. In China and other parts of Asia, up to 10% of the population is believed to be chronically infected. In addition to the significant burden of disease, CHB is responsible for 1 million deaths each year due to related complications such as liver failure, cirrhosis or hepatocellular carcinoma (liver cancer).

About TG4040

Transgene’s TG4040 vaccine candidate is a recombinant vector based on the MVA virus carrying and expressing three of the major non-structural proteins (NS3, NS4 and NS5B) of the hepatitis C virus (HCV). The MVA vector is a highly attenuated strain of vaccinia virus, which has been tested extensively in humans as a vaccine against smallpox and is known to strongly stimulate innate and adaptive immune responses to antigens.

About TG4040 Clinical Development Program

153 patients in the phase 2 HCVac study were recruited in five countries in Europe, in the United States and in Israel, and were randomized in one control arm (Arm A; 48 weeks of Peg-IFN/RBV) or one of the two experimental arms (Arms B and C). In the Arm B, the TG4040 dosage (subcutaneous injections at the dose of 107 pfu) was administered 6 times and Peg-IFN/RBV was given 4 weeks prior to the initiation of TG4040. In the Arm C, the TG4040 dosage was administered 13 times and Peg-IFN/RBV was introduced 12 weeks after the initiation TG4040. The HCVac trial investigated the efficacy and safety of these two different schedules of TG4040 administration in combination with Peg-IFN and RBV.

About Transgene:

Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for the treatment of cancers and infectious diseases. Transgene’s products are major technological breakthroughs. They use well tolerated viruses to indirectly or directly kill infected or cancerous cells. Its four most advanced products have generated proof of concept data in randomized clinical studies: in lung cancer (TG4010), liver cancer (Pexa-Vec), hepatitis C (TG4040) and HPV-related cervical lesions (TG4001). Transgene has concluded strategic agreements for the development of three of these products: an option agreement with Novartis for the development of TG4010, an in-licensing agreement with US-based Jennerex, Inc. to develop and market Pexa-Vec and a strategic collaboration with EORTC to develop TG4001 in cancer of the oropharynx. Transgene also has a non exclusive agreement with Sanofi/Genzyme for its future commercial production. With 280 employees, it is based in Strasbourg, France, and has operations in Lyon, China and the USA. Additional information about Transgene is available at www.transgene.fr.

Transgene Forward Looking Statements

This press release contains forward-looking statements notably referring to an anticipated future BLA filing date by Transgene. Such anticipated future BLA filing date is based on the current plan of product development and testing. This plan may change in the future and, as such, Transgene could be in a position not to meet the currently anticipated development milestones, including such BLA filing. For further information on the risks and uncertainties involved in the testing and development of Transgene’s product candidates, see Trangene’s Document de Référence on file with the French Autorité des marchés financiers on its website at http://www.amffrance.org and on Transgene’s website at www.transgene.fr .

Société anonyme au capital de 72.886.317 € – R.C. Strasbourg B 317 540 581
400 boulevard Gonthier d’Andernach – Parc d’Innovation - CS80166 – 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)
Tél : + 33 (0)3 88 27 91 00 

Contacts

Transgene
Philippe Archinard, +33 (0)3 88 27 91 22
Chairman & CEO
or
Stéphane Boissel, +33 (0)3 88 27 91 02
Executive Vice President & CFO
or
Elisabetta Castelli, +33 (0)3 88 27 91 21
Director IR
or
MC Services
Raimund Gabriel, +49 89 210 228 30
or
Shaun Brown, +44 207 148 5998

Hepatitis C;Therapeutic vaccine TG4040 (MVA-HCV)-Transgene announces Phase I clinical results

TRANSGENE : Publishes Phase I Clinical Data of its HCV Immunotherapy Product in Journal Gastroenterology and Announces Future Communication at AASLD
Regulatory News:
Detailed Phase I clinical results (Good safety and early antiviral efficacy)
Phase II (HCVac study) data will be presented at AASLD in early November
Transgene (NYSE Euronext: TNG) (Paris:TNG) today announces that detailed results of its Phase I open-label, dose-escalating study performed in France with its therapeutic vaccine TG4040 (MVA-HCV) in patients infected with chronic hepatitis C (HCV) are published in the September issue of Gastroenterology, which is now available online. It also announces that the initial Phase II data of the HCVac study will be presented at the upcoming AASLD (American Association for the Study of Liver Diseases) liver meeting to be held in San Francisco on November 3rd to 8th, 2011.
The published Phase I results, also highlighted in the August issue of Nature Reviews Gastroenterology and Hepatology, give a thorough analysis of safety data together with analysis of vaccine-induced immunogenicity and early antiviral efficacy, giving Hepatologists and Gastroenterologists the opportunity to view in more detail the results of this first clinical trial.
TG4040 is currently undergoing a large Phase II trial (the "HCVac" study) in patients with chronic HCV in combination with the standard of care, peg-IFN alpha and ribavirin. The initial primary end-point data, i.e. complete early virologic response ("cEVR"), have been selected for presentation at the next AASLD.
"We are encouraged by the increasing interest shown in TG4040 as a potential innovative treatment for chronic HCV infection. The good safety profile coupled with the novel mechanism of action, which is complementary to those currently exploited by small antiviral agents such as anti-proteases and anti-polymerases, make TG4040 a very attractive, innovative candidate to improve treatment of chronic HCV infection", said Philippe Archinard, Chairman and CEO of Transgene, adding further "We are now looking forward to presenting the HCVac primary end-point data at the upcoming AASLD meeting".
About TG4040
Transgene's TG4040 vaccine candidate is a recombinant vector-based on the MVA virus carrying and expressing three of the major non-structural proteins (NS3, NS4 and NS5B) of the hepatitis C virus ("HCV"). The MVA vector is a highly attenuated strain of vaccinia virus, which has been tested extensively in humans as a vaccine against smallpox and is known to strongly stimulate innate and adaptive immune responses to antigens.
About TG4040 clinical development program
Phase I clinical results in 39 treatment naive genotype 1 HCV patients showed that the product is safe and well tolerated at all dose levels tested. Immunological analyses on 15 treatment naive patients were encouraging and supported the expected mechanism of action of TG4040 which aims at inducing an effective HCV-specific T cell-based immune response, able to control viral replication.
Enrolment of patients for the Phase II HCVac trial was completed at the end of March 2011. One hundred and fifty three treatment naïve patients chronically infected with genotype 1 hepatitis C virus were recruited in 5 countries in Europe, the U.S. and Israel. Patients were randomized in the 3 arms of the study: one control arm without TG4040 and two experimental arms exploring the combination of TG4040 with standard of care (Pegylated-Interferon Alpha2a and Ribavarin). The HCVac trial investigates the efficacy and safety of two different schedules of administration of TG4040 and will measure the proportion of patients who achieve complete Early Virologic Response (cEVR) and Sustained Virologic Response (SVR) as well as the product's ability to elicit an immune response.
Primary end-point data i.e. complete early viral response ("cEVR") for all patients is expected by the fourth quarter of 2011, with final data (sustained virological response, "SVR") expected for the fourth quarter of 2012.
About chronic hepatitis C
Hepatitis C currently represents a major public health concern. The population chronically infected with HCV in the world is estimated at 170 to 200 million and hepatitis-C-related deaths at approximately 470,000 annually. Peak of prevalence of HCV-related diseases is expected to occur in 2025-2030 in developed countries.
HCV infection leads to liver diseases such as fibrosis, cirrhosis and liver carcinoma, which are the prime indications for liver transplants. The current standard of care for patients infected with the HCV genotype 1 (a combination of Pegylated Interferon Alpha and Ribavirin) is lengthy, often poorly tolerated and effective in only approximately 50% of patients completing therapy. In addition, a substantial number of patients never receive therapy. Therefore, there is a strong medical need for new alternative approaches, including combination therapies.
About Transgene (www.transgene.com)
Transgene, a member of the Institut Mérieux Group, is a publicly traded French bio-pharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases, and has five compounds in clinical development: TG4010 and JX594/TG6006 having completed initial Phase II trials, TG4001 in Phase IIb trial, TG4040 in Phase II trial and TG4023 in Phase I trial. Transgene has concluded strategic agreements for the development of two of its immunotherapy products, an option agreement with Novartis for the development of TG4010 to treat various cancers, and an in-licensing agreement with US-based Jennerex Biotherapeutics, Inc., to develop and market JX594/TG6006, an oncolytic virus.
Transgene has bio-manufacturing capacities for viral-based products. Additional information about Transgene is available on the internet at www.transgene.fr.
Cautionary note for Transgene regarding forward-looking statements This press release contains forward-looking statements referring to the clinical testing, development, and manufacturing of our products. Clinical testing and successful product development, manufacturing and commercialization depend on a variety of factors, including the timing and success of future patient enrolment, the risk of unanticipated adverse patient reactions,the capacity to manufacture products efficiently in accordance with Good Manufacturing Practices standards, regulatory approval and the level of demand for the product by the medical community. In addition, forward-looking statements regarding product development, testing, manufacturing and marketing costs are by their nature subject to uncertainties as a result of unforeseen difficulties and expenses which may arise, and future product development costs may exceed current expectations. For further
Société anonyme au capital de 72.470.137 ? - R.C. Strasbourg B 317 540 581Boulevard Gonthier d'Andernach - Parc d'Innovation - CS80166 - 67405 ILLKIRCH GRAFFENSTADEN CEDEX (France)Tél : + 33 3 88 27 91 00 Fax : + 33 3 88 27 91 11